Human pre-germinal center B cell [09-001]
Smoker without Lung Cancer (NC_Illumina)
RNA-Seq Lung Fibroblasts batch1, sample 1
RNA-Seq Lung Fibroblasts batch1, sample 2
Mitochondria PARE 5' end sequencing (rep1)
Mitochondria PARE 5' end sequencing (rep2)
Prostate cancer bone metastases bone_marrow_nugen1
Prostate cancer bone metastases bone_marrow_nugen2
Prostate cancer bone metastases bone_marrow_nugen3
Prostate cancer bone metastases bone_marrow_nugen4
Prostate cancer bone metastases bone_marrow_nugen5
Prostate cancer bone metastases bone_marrow_nugen6
Prostate cancer bone metastases bone_marrow_nugen7
Prostate cancer bone metastases bone_marrow_nugen8
Colon tissue from human s2,paracancerous
human GBM1 GSCs+BMI1 knockdown+BMP7+Arvanil+doxycycline rep
K562 cells with shRNA targeting SRF gene cultured with no doxycycline (uninduced - UI), rep1.
K562 cells with shRNA targeting SRF gene cultured with doxycycline for 48 hours (48 hr), rep1.
K562 cells with shRNA targeting SRF gene cultured with no doxycycline (uninduced - UI), rep2.
K562 cells with shRNA targeting SRF gene cultured with doxycycline for 48 hours (48 hr), rep2.
K562 cells with shRNA targeting EGR1 gene cultured with no doxycycline (uninduced - UI), rep1.
K562 cells with shRNA targeting EGR1 gene cultured with doxycycline for 72 hours (72 hr), rep1.
K562 cells with shRNA targeting EGR1 gene cultured with no doxycycline (uninduced - UI), rep2.
K562 cells with shRNA targeting EGR1 gene cultured with doxycycline for 72 hours (72 hr), rep2.
K562 cells with shRNA targeting ATF3 gene cultured with no doxycycline (uninduced - UI), rep1.
K562 cells with shRNA targeting ATF3 gene cultured with doxycycline for 24 hours (24 hr), rep1.
K562 cells with shRNA targeting ATF3 gene cultured with no doxycycline (uninduced - UI), rep2.
K562 cells with shRNA targeting ATF3 gene cultured with doxycycline for 24 hours (24 hr), rep2.
RNA-seq Induced and PA-treated Replicate 1
RNA-seq Induced and PA-treated Replicate 2
RNA-seq Induced and PS1145-treated Replicate 1
RNA-seq Induced and PS1145-treated Replicate 2
Endogenous small RNAs from human senescent fibroblast WI-38
bladder tissue from human s2, paracancerous
islet preparation 1 under control condition
islet preparation 1 under cytokine treatment
islet preparation 2 under control condition
islet preparation 2 under cytokine treatment
islet preparation 3 under control condition
islet preparation 3 under cytokine treatment
islet preparation 4 under control condition
islet preparation 4 under cytokine treatment
islet preparation 5 under control condition
islet preparation 5 under cytokine treatment
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D1-2
Treated with 0.25 ug/ml of Flageline and 20 ug/ml of 1018 for 4 hours. PBMC-CF patient D1-2
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D-2
Treated with 0.25 ug/ml of Flageline and 20 ug/ml of 1018 for 4 hours. PBMC-CF patient D-2
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D-3
Treated with 0.25 ug/ml of Flageline and 20 ug/ml of 1018 for 4 hours. PBMC-CF patient D-3
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D-4
Treated with 0.25 ug/ml of Flageline and 20 ug/ml of 1018 for 4 hours. PBMC-CF patient D-4
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D-5
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D1-2-27
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D1-2-32
Treated with Flageline at 0.25 ug/ml for 4 hours-PBMC-CF patient D1-2-33
mRNA-seq for vehicle treated PC3 cells, replicate #1.
mRNA-seq for rapamycin treated PC3 cells, replicate #1.
Footprint for rapamycin treated PC3 cells, replicate #1.
mRNA-seq for PP242 treated PC3 cells, replicate #1.
Footprint for PP242 treated PC3 cells, replicate #1.
mRNA-seq for vehicle treated PC3 cells, replicate #2.
Footprint for vehicle treated PC3 cells, replicate #2.
mRNA-seq for rapamycin treated PC3 cells, replicate #2.
Footprint for rapamycin treated PC3 cells, replicate #2.
mRNA-seq for PP242 treated PC3 cells, replicate #2.
Footprint for PP242 treated PC3 cells, replicate #2.
HepG2 exposed to BaP for 12h, biological rep 1
HepG2 exposed to BaP for 12h, biological rep 2
HepG2 exposed to BaP for 24h, biological rep 1
HepG2 exposed to BaP for 24h, biological rep 2
HepG2 exposed to DMSO for 12h, biological rep 1
HepG2 exposed to DMSO for 12h, biological rep 2
HepG2 exposed to DMSO for 24h, biological rep 1
HepG2 exposed to DMSO for 24h, biological rep 2
human DR-GFP/U2OS cells that were transfected with pCBASce plasmid and collected at 12 h post-transfection
human DR-GFP/U2OS cells that were transfected with pCBASce plasmid and collected at 16 h post-transfection
human DR-GFP/U2OS cells that were transfected with pCBASce plasmid and collected at 20 h post-transfection
human DR-GFP/U2OS cells that were transfected with pCBASce plasmid and collected at 24 h post-transfection
human DR-GFP/U2OS cells that were transfected with a control plasmid and collected at 20 h post-transfection
Acrolentiginous melanoma (3.0 mm, level IV)
Primary Cutaneous Melanoma1 (11.5 mm, level V)
Primary Cutaneous Melanoma2 (4.0 mm, level IV)
Primary Cutaneous Melanoma3 (2.8 mm, level IV)
Primary Cutaneous Melanoma4 (2.5 mm, level IV)
Primary Cutaneous Melanoma5 (2.0 mm, level IV)
chronic myeloid leukemia blood from human s1, in early disease
peripheral blood from sample 1, primary tumor
peripheral blood from sample 2, remission
partially differentiated ESC BG01 partial diff
Non-smoker female, NSCLC, smRNA-Seq [P1N]
Non-smoker female, NSCLC, smRNA-Seq [P1T]
Non-smoker female, NSCLC, smRNA-Seq [P3N]
Non-smoker female, NSCLC, smRNA-Seq [P3T]
Non-smoker female, NSCLC, smRNA-Seq [P4N]
Non-smoker female, NSCLC, smRNA-Seq [P4T]
Non-smoker female, NSCLC, smRNA-Seq [P5N]
Non-smoker female, NSCLC, smRNA-Seq [P5T]
Non-smoker female, NSCLC, smRNA-Seq [P6N]
Non-smoker female, NSCLC, smRNA-Seq [P6T]
Non-smoker female, NSCLC, smRNA-Seq [P8N]
Non-smoker female, NSCLC, smRNA-Seq [P8T]
Transcription Start Site Sequencing of PrEC Cells
Transcription Start Site Sequencing of LNCaP Cells
Universal human reference RNA HCT20320-UHR0.01ng
Universal human reference RNA HCT20321-UHR0.01ng
Universal human reference RNA HCT20322-UHR0.01ng
Universal human reference RNA HCT20323-UHR0.01ng
Universal human reference RNA HCT20325-UHR0.01ng
Universal human reference RNA HCT20410-UHR1ng
Universal human reference RNA HCT20411-UHR0.1ng
Universal human reference RNA HCT20412-UHR0.01ng
Universal human reference RNA s_3_HCT21003-UHR-10ng
Universal human reference RNA s_3_HCT21011-UHR-100pg
Universal human reference RNA s_4_HCT21004-UHR-10ng
Universal human reference RNA s_4_HCT21012-UHR-100pg
Universal human reference RNA s_5_HCT21021-UHR-10pg
Universal human reference RNA s_6_HCT21022-UHR-10pg
Universal human reference RNA s_7_HCT21007-UHR-1ng
Universal human reference RNA s_7_HCT21015-UHR-10pg
Universal human reference RNA s_7_HCT21023-UHR-10pg
Universal human reference RNA s_8_HCT21008-UHR-1ng
Universal human reference RNA s_8_HCT21016-UHR-10pg
Universal human reference RNA s_8_HCT21024-UHR-10pg
Day 4 differentiated H1 (human embryonic stem cell) derived EMHlin-KDRbrightAPLNR+PDGFRalow/- cells [duplicate_1of2]
Day 4 differentiated H1 derived KDRdim cells
Day 5 differentiated H1 derived VE-cadherin+CD73-CD43+CD235a+CD41a+ cells
Day 5 differentiated H1 derived VE-cadherin+CD73-CD43lowCD235a+CD41a-CD117- cells [duplicate_1of2]
Day 3 differentiated H1 derived endothelial cores from hemangioblast colonies
Day 8 differentiated H1 derived CD34+CD43+CD235a/CD41a+CD45- cells
Day 8 differentiated H1 derived lin-CD34+CD43+CD235a/CD41a-CD45- cells
Day 8 differentiated H1 derived lin-CD34+CD43+CD235a/CD41a-CD45+ cells
Human umbelical vein endothelial cells derived RNA
Day 3 differentiated H1 derived EMHlin-APLNR+PDGFRa+ cells
Day 4 differentiated H1 (human embryonic stem cell) derived EMHlin-KDRbrightAPLNR+PDGFRalow/- cells [duplicate_2of2]
Day 4 differentiated H1 derived KDRbright VE-cadherin+ cells
Day 5 differentiated H1 derived VE-cadherin+CD73-CD235a/CD43-CD117intermediate cells
Day 5 differentiated H1 derived VE-cadherin+CD73-CD43lowCD235a+CD41a-CD117- cells [duplicate_2of2]
Day 5 differentiated H1 derived VE-cadherin+CD73+CD235a/CD43-CD117high cells
H1 derived endothelial cells at passage 2
BF RNASeq (biological replicate 1 and 2)
HS RNASeq (biological replicate 1 and 2)
Small RNA from HeLa cell total RNA treated with siLuc
Small RNA from HeLa cell total RNA treated with siADAR1
adjacent normal tissue without Transcatheter Arterial Infusion chemotherapy
tumor tissue without Transcatheter Arterial Infusion chemotherapy
adjacent normal tissue with Transcatheter Arterial Infusion chemotherapy
tumor tissue with Transcatheter Arterial Infusion chemotherapy
MiaPaCa-2 cells treated with DMEM  [Mia-DMEM]
MiaPaCa-2 cells treated with calcipotriol  [Mia-CAL]
MiaPaCa-2 cells treated with conditioned media  [Mia-CM]
MiaPaCa-2 cells treated with conditioned media [Mia-CMS]
LNCaP DHT treated [RNA-seq replicate 1 ]
LNCaP DHT treated [RNA-seq replicate 2 ]
GRO-seq_Vehicle  (Re-Sequenced GSM678535 to greater depth)
GRO-seq_Vehicle  (Re-Sequenced GSM678536 to greater depth)
GRO-seq_E2_10m (Re-Sequenced GSM678537 to greater depth)
GRO-seq_E2_10m (Re-Sequenced GSM678538 to greater depth)
GRO-seq_E2_40m (Re-Sequenced GSM678539 to greater depth)
GRO-seq_E2_40m (Re-Sequenced GSM678540 to greater depth)
mRNA-seq, RAD21cv HEK293, TEV treated, replicate one
mRNA-seq, RAD21cv HEK293, TEV treated, replicate two
mRNA-seq, RAD21cv HEK293, HRV treated, replicate one
mRNA-seq, RAD21cv HEK293, HRV treated, replicate two
mRNA-seq, HEK293 siRNA Control, replicate one
mRNA-seq, HEK293 siRNA Control, replicate two
mRNA-seq, HEK293 siRNA CTCF, replicate one
mRNA-seq, HEK293 siRNA CTCF, replicate two
non-silencing control siRNA technical replicate 1
non-silencing control siRNA technical replicate 2
non-silencing control siRNA technical replicate 3
TCF21 knockdown siRNA technical replicate 1
TCF21 knockdown siRNA technical replicate 2
TCF21 knockdown siRNA technical replicate 3
IFN-g stimulated HT-29 cells run at 25M reads
IFN-g stimulated HT-29 cells run at 50M reads
microRNA from sample A constructed by the kit from Bioo scientific  [LW_AB_1]
microRNA from sample A constructed by the kit from Bioo scientific  [LW_AB_2]
microRNA from sample A constructed by the kit from NEB  [LW_AN_1]
microRNA from sample A constructed by the kit from NEB  [LW_AN_2]
microRNA from sample A constructed by the kit from Illumina [LW_AI_1]
microRNA from sample A constructed by the kit from Illumina [LW_AI_2]
microRNA from sample B constructed by the kit from Bioo scientific  [LW_BB_1]
microRNA from sample B constructed by the kit from Bioo scientific  [LW_BB_2]
microRNA from sample B constructed by the kit from NEB  [LW_BN_1]
microRNA from sample B constructed by the kit from NEB  [LW_BN_2]
microRNA from sample C constructed by the kit from Bioo scientific  [LW_CB_1]
microRNA from sample C constructed by the kit from Bioo scientific  [LW_CB_2]
microRNA from sample C constructed by the kit from NEB  [LW_CN_1]
microRNA from sample C constructed by the kit from NEB  [LW_CN_2]
Hepatoblast derived from HUES64 RNA-Seq reps1and2
Wild Type Staufen associated, RNase treated mRNA
sRNAs from siCtl transfected and SINV-infected HEK293 cells
sRNAs from siRNaseL transfected and SINV-infected HEK293 cells
sRNAs from non-infected HEK293 cells, non-treated with NaIO4
sRNAs from non-infected HEK293 cells, treated with NaIO4
sRNAs from SINV-infected HEK293 cells, non-treated with NaIO4
sRNAs from SINV-infected HEK293 cells, treated with NaIO4
serum + spiked miRs constant concentration
serum + spiked miRs constant concentration repeat
serum + spiked miRs variable concentration
serum + spiked miRs variable concentration repeat
GM12878 native deproteinized followed by renatured RNA, V1
GM12878 native deproteinized followed by renatured RNA, S1
GM12878 native deproteinized replicate 1, S1
GM12878 native deproteinized replicate 1, V1
GM12878 native deproteinized replicate 2, S1
GM12878 native deproteinized replicate 2, V1
hESCs transfected with control siRNA - replicate 1
hESCs transfected with control siRNA - replicate 2
hESCs transfected with control siRNA - replicate 3
hESCs transfected with LIN-41 #1 siRNA - replicate 1
hESCs transfected with LIN-41 #1 siRNA - replicate 2
hESCs transfected with LIN-41 #1 siRNA - replicate 3
hESCs transfected with LIN-41 #2 siRNA - replicate 1
hESCs transfected with LIN-41 #2 siRNA - replicate 2
hESCs transfected with LIN-41 #2 siRNA - replicate 3
miR-124 transfection to HeLa, replicate 1
miR-124 transfection to HeLa, replicate 2
miR-155 transfection to HeLa, replicate 1
miR-155 transfection to HeLa, replicate 2
miR-124 transfection to HEK293, replicate 1
miR-124 transfection to HEK293, replicate 2
miR-155 transfection to HEK293, replicate 1
miR-155 transfection to HEK293, replicate 2
Mock transfection to HEK293, replicate 1
Mock transfection to HEK293, replicate 2
miR-124 transfection to Huh7, replicate 1
miR-124 transfection to Huh7, replicate 2
miR-155 transfection to Huh7, replicate 1
miR-155 transfection to Huh7, replicate 2
miR-124 transfection to IMR90, replicate 1
miR-124 transfection to IMR90, replicate 2
Oral Cancer Favorable 5-year survival Y001
Oral Cancer Favorable 5-year survival Y002
Oral Cancer Favorable 5-year survival Y004
Oral Cancer Favorable 5-year survival Y003
Oral Cancer Favorable 5-year survival Y005
Oral Cancer Favorable 5-year survival Y006
Oral Cancer Favorable 5-year survival Y007
Oral Cancer Favorable 5-year survival Y008
Oral Cancer Favorable 5-year survival Y009
Oral Cancer Favorable 5-year survival Y010
Total RNA with p37, p40, p42, p45 overexpresion
sRNAs from DG-75 cells stably expressing KSHV pri-miR-K10/12
control MCF7L-shPTEN cells (no DOX, no reduced PTEN)
MCF7L-shPTEN cells with DOX, and reduced PTEN
child patient T3 (microcephaly), mutation CLP1 R140H
child patient T4 (microcephaly), mutation CLP1 R140H
Luciferase knockdown in PC3 cells using shRNa replicate 1
Luciferase knockdown in PC3 cells using shRNa replicate 2
Luciferase knockdown in PC3 cells using shRNa replicate 3
c-Jun knockdown in PC3 cells using shRNa replicate 1
c-Jun knockdown in PC3 cells using shRNa replicate 2
c-Jun knockdown in PC3 cells using shRNa replicate 3
Jun-D knockdown in PC3 cells using shRNa replicate 1
Jun-D knockdown in PC3 cells using shRNa replicate 2
Jun-D knockdown in PC3 cells using shRNa replicate 3
islet preparation 1 under palmitate exposure
islet preparation 2 under palmitate exposure
islet preparation 3 under palmitate exposure
islet preparation 4 under palmitate exposure
islet preparation 5 under palmitate exposure
Scr_1 (control160) alternative name, Control 1
Scr_2 (control_L1) alternative name, Control 2
Scr_3 (Contr01) alternative name, Control 3
Small RNA deep sequencing of mock-infected KMB17 cells 21 days post-infection
Human BT474 breast cancer cell line under trastuzumab treatment
Human HCC1954 breast cancer cell line under trastuzumab treatment
Trastuzumab resistant version of the human BT474 breast cancer cell line
Trastuzumab resistant version of the human BT474 breast cancer cell line under trastuzumab treatment
Monolayer AEC stimulated with flagellin replicate 1
Monolayer AEC stimulated with flagellin replicate 2
ALI AEC stimulated with flagellin replicate 1
ALI AEC stimulated with flagellin replicate 2
H3.3cs1-induced senescence early time point
H3.3cs1-induced senescence late time point
mRNA from ADAR1 KD Day 17 (Motor Neuron)
mRNA from ADAR1 KD Day 35 (Motor Neuron)
sRNA from ADAR1 KD Day 17 (Motor Neuron)
sRNA from ADAR1 KD Day 35 (Motor Neuron)
RNA-Seq analysis in CUTLL1 cells upon treatment with short hairpin against JMJD3 replicate 1
RNA-Seq analysis in CUTLL1 cells upon treatment with short hairpin against JMJD3 replicate 2
RNA-Seq analysis in CUTLL1 cells upon treatment with short hairpin against JMJD3 replicate 3
RNA-Seq analysis in CUTLL1 cells upon treatment with short hairpin against UTX replicate 1
RNA-Seq analysis in CUTLL1 cells upon treatment with short hairpin against UTX replicate 2
RNA-Seq analysis in CUTLL1 cells upon treatment with short hairpin against RENILLA replicate 1
RNA-Seq analysis in CUTLL1 cells upon treatment with short hairpin against RENILLA replicate 2
RNA-Seq analysis in CUTLL1 cells upon treatment with short hairpin against RENILLA replicate 3
RNA-Seq analysis in CEM cells upon treatment with short hairpin against JMJD3 replicate 1
RNA-Seq analysis in CEM cells upon treatment with short hairpin against JMJD3 replicate 2
RNA-Seq analysis in CEM cells upon treatment with short hairpin against UTX replicate 1
RNA-Seq analysis in CEM cells upon treatment with short hairpin against UTX replicate 2
RNA-Seq analysis in CEM cells upon treatment with short hairpin against RENILLA replicate 2
RNA-Seq analysis in CEM cells upon treatment with short hairpin against RENILLA replicate 1
C02182 Idiopathic Dilated CMP Left Ventricle
P00333 Idiopathic Dilated CMP Left Ventricle
RNA-Seq analysis in HCT116 FBXW7 KO cells upon heat shock treatment replicate 1
RNA-Seq analysis in HCT116 FBXW7 KO cells upon heat shock treatment replicate 2
RNA-Seq analysis in HCT116 FBXW7 KO cells after recovery from heat shock treatment replicate 1
RNA-Seq analysis in HCT116 FBXW7 KO cells after recovery from heat shock treatment replicate 2
RNA-Seq analysis in HCT116 WT cells upon heat shock treatment replicate 1
RNA-Seq analysis in HCT116 WT cells upon heat shock treatment replicate 2
RNA-Seq analysis in HCT116  WT cells after recovery from heat shock treatment replicate 1
RNA-Seq analysis in HCT116 WT cells after recovery from heat shock treatment replicate 2
Control B cell RNASeq biological replicate 1
Control B cell RNASeq biological replicate 2
BZLF1 B cell RNASeq biological replicate 1
BZLF1 B cell RNASeq biological replicate 2
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_001)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_002)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_003)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_004)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_006)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_007)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_005)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_008)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_009)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_012)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_013)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_016)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_015)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_017)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_018)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_021)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_025)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_027)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_023)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_022)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_024)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_029)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_026)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_030)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_032)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_037)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_043)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_040)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_046)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_045)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_049)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_048)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_051)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_047)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_050)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_052)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_053)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_056)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_057)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_058)
CD Male with Microscopic inflammation and Deep Ulcer (CCFA_Risk_059)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_060)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_061)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_063)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_066)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_068)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_062)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_069)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_070)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_071)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_073)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_074)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_075)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_091)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_093)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_094)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_096)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_097)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_095)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_098)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_100)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_099)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_101)
CD Female with Undetermined and No Deep Ulcer (CCFA_Risk_102)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_103)
CD Male with Undetermined and No Deep Ulcer (CCFA_Risk_104)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_106)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_105)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_107)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_108)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_109)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_110)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_111)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_112)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_113)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_115)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_116)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_132)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_134)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_135)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_133)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_140)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_141)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_136)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_138)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_137)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_139)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_142)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_146)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_145)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_147)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_150)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_148)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_156)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_149)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_158)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_157)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_159)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_161)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_160)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_162)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_163)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_164)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_165)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_166)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_167)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_168)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_169)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_171)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_172)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_170)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_173)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_174)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_175)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_176)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_177)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_178)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_179)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_182)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_181)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_183)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_184)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_188)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_190)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_191)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_186)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_187)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_193)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_189)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_194)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_195)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_196)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_199)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_197)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_198)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_200)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_201)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_202)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_203)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_204)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_205)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_208)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_206)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_207)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_209)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_210)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_213)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_212)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_211)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_214)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_216)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_217)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_215)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_218)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_219)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_221)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_220)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_223)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_222)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_224)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_225)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_227)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_228)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_229)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_231)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_230)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_236)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_237)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_252)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_253)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_255)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_256)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_257)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_258)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_261)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_260)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_263)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_264)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_265)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_268)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_266)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_269)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_267)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_270)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_271)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_273)
CD Male with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_262)
CD Female with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_275)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_274)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_276)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_278)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_279)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_281)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_285)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_286)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_287)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_289)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_293)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_296)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_299)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_303)
CD Male with Macroscopic inflammation and Deep Ulcer (CCFA_Risk_300)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_304)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_307)
CD Female with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_309)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_311)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_310)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_312)
CD Male with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_314)
CD Female with Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_313)
CD Male with Microscopic inflammation and No Deep Ulcer (CCFA_Risk_317)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_320)
CD Female with No Microscopic or Macroscopic inflammation and No Deep Ulcer (CCFA_Risk_321)
CUTLL1 carrying an shRNA targeting Renilla_2
CUTLL1 carrying an shRNA targeting Renilla_1
CUTLL1 carrying an shRNA targeting Renilla_3
CUTLL1 carrying an shRNA targeting Renilla_4
CUTLL1 carrying an shRNA targeting Renilla_5
CUTLL1 carrying an shRNA targeting LUNAR1_1
CUTLL1 carrying an shRNA targeting LUNAR1_2
CUTLL1 carrying an shRNA targeting LUNAR1_4
CUTLL1 carrying an shRNA targeting LUNAR1_3
CUTLL1 carrying an shRNA targeting LUNAR1_5
CUTLL1 carrying a second shRNA targeting LUNAR1_1
CUTLL1 carrying a second shRNA targeting LUNAR1_2
CUTLL1 carrying a second shRNA targeting LUNAR1_3
CUTLL1 carrying a second shRNA targeting LUNAR1_4
CUTLL1 carrying a second shRNA targeting LUNAR1_5
RNA-seq: LV sh-empty transduced ES cells
RNA-seq: LV sh-TRIM28 transduced ES cells
RNA-seq: LV sh-non specific transduced ES cells
P493-6 treated with doxycycline(Myc Low)
P493-6 treated with KJ-Pyr-9 and doxycycline
RNA-seq of LV sh-empty transduced hES cells
RNA-seq of LV sh-DNMTs transduced hES cells
BD patient, Li-responder + Lithium (R1 Li)
BD patient, Li-responder + Lithium (R2 Li)
BD patient, Li-responder + Lithium (R3 Li)
BD patient, Li-non-responder + Lithium (N1 Li)
BD patient, Li-non-responder + Lithium (N2 Li)
BD patient, Li-non-responder + Lithium (N3 Li)
Luciferase knockdown in DU145 cells using shRNA replicate 1
Luciferase knockdown in DU145 cells using shRNA replicate 2
Luciferase knockdown in DU145 cells using shRNA replicate 3
ETS1 knockdown in DU145 cells using shRNA replicate 1
ETS1 knockdown in DU145 cells using shRNA replicate 2
ETS1 knockdown in DU145 cells using shRNA replicate 3
Il-4-stimulated keratinocytes (3h) Day 02 sample1
Il-4-stimulated keratinocytes (3h) Day 02 sample2
Il-4-stimulated keratinocytes (24h) Day 02 sample1
Il-4-stimulated keratinocytes (24h) Day 02 sample2
Control keratinocytes (120h) Day 05 sample1
Control keratinocytes (120h) Day 05 sample2
Il-4-stimulated keratinocytes  (120h) Day 05 sample1
Il-4-stimulated keratinocytes (120h) Day 05 sample2
Control siRNA keratinocytes plus IL-4 (24h) Day02 sample1
Control siRNA keratinocytes plus IL-4 (24h) Day02 sample2
STAT6 siRNA keratinocytes plus IL-4 (24h) Day02 sample1
STAT6 siRNA keratinocytes plus IL-4 (24h) Day02 sample2
negative control siRNA treated MDA-MB-231 cells 1
negative control siRNA treated MDA-MB-231 cells 2
negative control siRNA treated MDA-MB-231 cells 3
TRA2A/B siRNA treated MDA-MB-231 cells 1
TRA2A/B siRNA treated MDA-MB-231 cells 2
TRA2A/B siRNA treated MDA-MB-231 cells 3
RNA-seq siCont ActD 0h (biological replicate #2)
RNA-seq siCont ActD 1h (biological replicate #2)
RNA-seq siCont ActD 2h (biological replicate #2)
RNA-seq siCont ActD 4h (biological replicate #2)
RNA-seq siTUT47 ActD 0h (biological replicate #2)
RNA-seq siTUT47 ActD 2h (biological replicate #2)
RNA-seq siTUT47 ActD 1h (biological replicate #2)
RNA-seq siTUT47 ActD 4h (biological replicate #2)
mock-transfected U2OS poly(A)-selected total RNA
mock-transfected U2OS tRNA and rRNA depleted RNA
miR-1-transfected U2OS poly(A)-selected total RNA
miR-1-transfected U2OS poly(A)-selected cytoplasmic RNA
miR-1-transfected U2OS tRNA and rRNA depleted RNA
mock-transfected U2OS poly(A)-selected cytoplasmic RNA
miR-155-transfected U2OS poly(A)-selected total RNA
miR-155-transfected U2OS poly(A)-selected cytoplasmic RNA
miR-155-transfected U2OS tRNA and rRNA depleted RNA
Day 1 post NGN induction, biological replicate 1
Day 1 post NGN induction, biological replicate 2
Day 1 post NGN induction, biological replicate 3
Day 3 post NGN induction, biological replicate 1
Day 3 post NGN induction, biological replicate 2
Day 3 post NGN induction, biological replicate 3
Day 4 post NGN induction, biological replicate 1
Day 4 post NGN induction, biological replicate 2
Day 4 post NGN induction, biological replicate 3
Control arm, patient-derived tumor xenograft CRC020
cabozantinib treated arm, patient-derived tumor xenograft CRC020
Control arm, patient-derived tumor xenograft CRC098
cabozantinib treated arm, patient-derived tumor xenograft CRC098
Control arm, patient-derived tumor xenograft CRC102
cabozantinib treated arm, patient-derived tumor xenograft CRC102
Level 2 promoters in human ESCs and NESCs
PRDM12 wildtype female (control to D31Y)
BCR-ABL inhibitor-resistant KCL-22 single clone #1
BCR-ABL inhibitor-resistant KCL-22 single clone #4
BCR-ABL inhibitor-resistant KCL-22 single clone #2
BCR-ABL inhibitor-resistant KCL-22 single clone #3
control transfection Replicate 1 (miR-106a_transfections_Hela)
control transfection Replicate 2 (miR-106a_transfections_Hela)
RNA-7 transfection Replicate 1 (miR-106a_transfections_Hela)
RNA-7 transfection Replicate 2 (miR-106a_transfections_Hela)
pre-miR-106a transfection Replicate 1 (miR-106a_transfections_Hela)
pre-miR-106a transfection Replicate 2 (miR-106a_transfections_Hela)
GFP control, overexpressed in HMEC cells 1
GFP control, overexpressed in HMEC cells 2
GFP control, overexpressed in HMEC cells 3
GFP control, overexpressed in HMEC cells 4
GFP control, overexpressed in HMEC cells 5
GFP control, overexpressed in HMEC cells 6
GFP control, overexpressed in HMEC cells 7
GFP control, overexpressed in HMEC cells 8
GFP control, overexpressed in HMEC cells 9
GFP control, overexpressed in HMEC cells 10
GFP control, overexpressed in HMEC cells 11
GFP control, overexpressed in HMEC cells 12
human HER2/ERBB2, overexpressed in HMEC cells 1
human HER2/ERBB2, overexpressed in HMEC cells 2
human HER2/ERBB2, overexpressed in HMEC cells 3
human HER2/ERBB2, overexpressed in HMEC cells 4
human HER2/ERBB2, overexpressed in HMEC cells 5
Bulk mRNA sequencing data from SKBR3 cells
single cell mRNA sequencing data from single SKBR3 cells obtained with the DR-seq protocol
Human endothelial siRNA EPAS1 knockdown rep2
Human endothelial siRNA EPAS1 knockdown rep1
Human endothelial siRNA EPAS1 knockdown rep3
Day 14 Control Neural Progenitior Cells, Replicate 1
Day 14 Control Neural Progenitior Cells, Replicate 2
Day 14 Control Neural Progenitior Cells, Replicate 3
Day 14 Fgf2-treated Neural Progenitor Cells, Replicate1
Day 14 Fgf2-treated Neural Progenitor Cells, Replicate2
Day 14 Fgf2-treated Neural Progenitor Cells, Replicate3
iPSC 7dupASD2-C2 (GDB-242_J) ribo-zero RNAseq
iPSC WBS3-C2 (GDB-361_O) ribo-zero RNAseq
iPSC WBS4-C1 (GDB-306_O) ribo-zero RNAseq
iPSC 7dupASD1-C2 (GDB-Cf_G) ribo-zero RNAseq, biological replicate 1
iPSC 7dupASD1-C2 (GDB-Cf_G) ribo-zero RNAseq, biological replicate 2
iPSC AtWBS1-C2 (GDB-192_B) ribo-zero RNAseq
iPSC WBS1-C3 (GDB-339_C7) ribo-zero RNAseq
iPSC 7dupASD2-C1 (GDB-242_K) ribo-zero RNAseq
iPSC CTL1R-C2 (GDB-339-1_R) ribo-zero RNAseq
iPSC WBS1-C1 (GDB-339_C2) ribo-zero RNAseq
iPSC CTL1R-C3 (GDB-339-1_S) ribo-zero RNAseq
iPSC AtWBS1-C3 (GDB-192_D) ribo-zero RNAseq
iPSC 7dupASD1-C1 (GDB-Cf_C) polyA RNAseq
iPSC 7dupASD1-C3 (GDB-Cf_F) polyA RNAseq
iPSC 7dupASD1-C2 (GDB-Cf_G) polyA RNAseq
iPSC 7dupASD1-C2 (GDB-Cf_G) Scramble, ribo-zero RNAseq
iPSC 7dupASD1-C2 (GDB-Cf_G) GTF2I KD, ribo-zero RNAseq
iPSC 7dupASD2-C1 (GDB-242_K) Scramble, ribo-zero RNAseq
iPSC 7dupASD2-C1 (GDB-242_K) GTF2I KD, ribo-zero RNAseq
iPSC CTL1R-C1 (GDB-339-1_B) Scramble, ribo-zero RNAseq
iPSC CTL1R-C1 (GDB-339-1_B) GTF2I KD, ribo-zero RNAseq
iPSC WBS2-C2 (GDB-316_M) Scramble, ribo-zero RNAseq
iPSC WBS2-C2 (GDB-316_M) GTF2I KD, ribo-zero RNAseq
iPSC WBS4-C1 (GDB-306_O) Scramble, ribo-zero RNAseq
iPSC WBS4-C1 (GDB-306_O) GTF2I KD, ribo-zero RNAseq
iPSC AtWBS1-C2 (GDB-192_B) Scramble, ribo-zero RNAseq
iPSC AtWBS1-C2 (GDB-192_B) GTF2I KD, ribo-zero RNAseq
iPSC CTL1R-C3 (GDB-339-1_S) Scramble, ribo-zero RNAseq
iPSC CTL1R-C3 (GDB-339-1_S) GTF2I KD, ribo-zero RNAseq
MSC 7dupASD1-C2 (GDB-Cf_G) ribo-zero RNAseq
MSC AtWBS1-C2 (GDB-192_B) ribo-zero RNAseq
MSC 7dupASD2-C1 (GDB-242_K) ribo-zero RNAseq
MSC WBS2-C1 (GDB-316_M) ribo-zero RNAseq
MSC WBS4-C1 (GDB-306_O) ribo-zero RNAseq
MSC CTL1R-C3 (GDB-339-1_S) ribo-zero RNAseq
MSC WBS1-C1 (GDB-339_C2) ribo-zero RNAseq
polyA+ RNA from the cytoplasmic fraction-E2, rep 1
polyA+ RNA from the cytoplasmic fraction-E2, rep 2
polyA+ RNA from the cytoplasmic fraction+E2, rep 1
polyA+ RNA from the nuclear fraction-E2, rep 1
polyA+ RNA from the nuclear fraction-E2, rep 2
polyA+ RNA from the cytoplasmic fraction+E2, rep 2
polyA+ RNA from the nuclear fraction+E2, rep 1
polyA+ RNA from the nuclear fraction+E2, rep 2
polyA+ RNA from the chromatin fraction-E2, rep 1
polyA+ RNA from the chromatin fraction-E2, rep 2
polyA+ RNA from the chromatin fraction+E2, rep 1
polyA+ RNA from the chromatin fraction+E2, rep 2
WT control NCCIT Ribosome profiling (RPF)
LNCaP cells Control, biological replicate 2
LNCaP cells Control, biological replicate 1
LNCaP cells Control, biological replicate 3
LNCaP cells DHT treated biological replicate 1
LNCaP cells DHT treated biological replicate 2
LNCaP cells DHT treated biological replicate 3
Cytosolic Hsp60 depletion and TNF-alpha negative
Cytosolic Hsp60 depletion and TNF-alpha positive
Cytosolic Hsp60 normal and TNF-alpha positive
Cytosolic Hsp60 normal and TNF-alpha negative
human K562 pure RNA control (953 samples)
Hyperactivated MYC and depleted BUD31, replicate 3
Hyperactivated MYC and depleted BUD31, replicate 2
Hyperactivated MYC and depleted BUD31, replicate 1
Normal colon acquired during surgery for small intestine neuroendocrine tumor, female age 49 [RNA-Seq, 50_NIBD_NI]
B2/stricturing Crohn's disease [RNA-Seq, 440_CD_NI_B2]
Normal colon acquired during surgery for adenoma, male age 70 [RNA-Seq, 48_NIBD_NI]
Normal colon acquired during surgery for adenoma, male age 62 [RNA-Seq, 49_NIBD_NI]
Normal colon acquired during surgery for colonic inertia, female age 45 [RNA-Seq, 43_NIBD_NI]
Normal colon acquired during surgery for colon cancer, male age 52 [RNA-Seq, 39_NIBD_NI]
Normal colon acquired during surgery for large polyp, male age 65 [RNA-Seq, 42_NIBD_NI]
Normal colon acquired during surgery for colonic inertia, female age 41 [RNA-Seq, 36_NIBD_NI]
Normal colon acquired during surgery for colon cancer, male age 44 [RNA-Seq, 32_NIBD_NI]
Normal colon acquired during surgery for diverticulitis, male age 70 [RNA-Seq, 27_NIBD_NI]
Normal colon biopsy acquired during surgery for diverticulitis,female age 60 [RNA-Seq, 25_NIBD_NI]
Normal colon biopsy acquired during surgery for colon cancer, female age 82 [RNA-Seq, 30_NIBD_NI]
Normal colon biopsy, female age 53 [RNA-Seq, 22_NIBD_NI]
Normal colon acquired during Hartmann reversal after colon cancer, male age 52 [RNA-Seq, 23_NIBD_NI]
B3/penetrating Crohn's disease [RNA-Seq, 450_CD_NI_B3]
B3/penetrating Crohn's disease [RNA-Seq, 434_CD_NI_B3]
B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 429_CD_NI_B1]
B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 431_CD_NI_B1]
B3/penetrating Crohn's disease [RNA-Seq, 424_CD_NI_B3]
B2/stricturing Crohn's disease [RNA-Seq, 422_CD_NI_B2]
B2/stricturing Crohn's disease [RNA-Seq, 420_CD_NI_B2]
B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 408_CD_NI_B1]
B3/penetrating Crohn's disease [RNA-Seq, 413_CD_NI_B1]
B3/penetrating Crohn's disease [RNA-Seq, 407_CD_NI_B3]
B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 405_CD_NI_B1]
B3/penetrating Crohn's disease [RNA-Seq, 64_CD_NI_B3]
B3/penetrating Crohn's disease [RNA-Seq, 62_CD_NI_B3]
B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 63_CD_NI_B1]
B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 54_CD_NI_B1]
B2/stricturing Crohn's disease [RNA-Seq, 51_CD_NI_B2]
B3/penetrating Crohn's disease [RNA-Seq, 29_CD_NI_B3]
B2/stricturing Crohn's disease [RNA-Seq, 21_CD_NI_B2]
B2/stricturing Crohn's disease [RNA-Seq, 20_CD_NI_B2]
Overexpression of U2AF1_v3_S34F after U2AF1 knockdown, replicate 2
Overexpression of U2AF1_v3_wildtype after U2AF1 knockdown, replicate 2
Overexpression of U2AF1_v1_S34F after U2AF1 knockdown, replicate 2
Overexpression of U2AF1_v1_wildtype after U2AF1 knockdown, replicate 2
U2AF1 knockdown (Overexpression of empty vector after U2AF1 knockdown), replicate 2
Negative control (empty vector, control siRNA), replicate 2
Overexpression of U2AF1_v3_S34F after U2AF1 knockdown, replicate 1
Overexpression of U2AF1_v3_wildtype after U2AF1 knockdown, replicate 1
Overexpression of U2AF1_v1_S34F after U2AF1 knockdown, replicate 1
Overexpression of U2AF1_v1_wildtype after U2AF1 knockdown, replicate 1
U2AF1 knockdown (Overexpression of empty vector after U2AF1 knockdown), replicate 1
Negative control (empty vector, control siRNA), replicate 1
Human-mouse 12.5 cells / ul (~570 STAMPs)
Mel202 parental cells repeat #1 minus Shld
Mel202 parental cells repeat #1 plus Shld
RNA-Seq 786-O with HIF-2a over-expression 3
RNA-Seq 786-O with HIF-2a over-expression 2
RNA-Seq 786-O with HIF-2a over-expression 1
RNA-Seq 786-O with HIF-1a re-expression 3
RNA-Seq 786-O with HIF-1a re-expression 2
RNA-Seq 786-O with HIF-1a re-expression 1
SPI-2 (in vivo) pinT vector 5 min ara replicate 2
SPI-2 (in vivo) empty vector 5 min ara replicate 2
SPI-2 (in vivo) pinT vector 5 min ara replicate 1
SPI-2 (in vivo) empty vector 5 min ara replicate 1
SPI-2 (in vitro) empty vector 5 min ara replicate 2
SPI-2 (in vitro) pinT vector 5 min ara replicate 2
SPI-2 (in vitro) pinT vector 5 min ara replicate 1
SPI-1 empty vector 5 min ara replicate 2
SPI-2 (in vitro) empty vector 5 min ara replicate 1
SPI-1 empty vector 5 min ara replicate 1
mRNA-seq from M cells, pretreated with cycloheximide_2
mRNA-seq from M cells, pretreated with cycloheximide_1
mRNA-seq from G2 cells, pretreated with cycloheximide_2
mRNA-seq from G1 cells, pretreated with cycloheximide_2
mRNA-seq from G2 cells, pretreated with cycloheximide_1
mRNA-seq from G1 cells, pretreated with cycloheximide_1
Single cell mRNA sequencing data from KMB7 cells
RNA-seq at 24 h 1,25(OH)2D3, replicate C
RNA-seq at 2.5 h 1,25(OH)2D3, replicate C
RNA-seq at 24 h 1,25(OH)2D3, replicate B
RNA-seq at 2.5 h 1,25(OH)2D3, replicate B
RNA-seq at 24 h 1,25(OH)2D3, replicate A
RNA-seq at 2.5 h 1,25(OH)2D3, replicate A
mesoderm differentiated cells from PBMC SC12-037MESO
mesoderm differentiated cells from Fibroblast SC12-030MESO
mesoderm differentiated cells from Cord blood SC13-045MESO
mesoderm differentiated cells from Fibroblast SC12-022
FACS sorted CD (45+/34+/33+/123+) from Bone marrow SC12-042.1-GMP
FACS sorted CD (45+/34+/33+/123+) from Bone marrow SC12-042.2-GMP
FACS sorted CD (45+/34-/33+/11b-/15+)  from Bone marrow RN19-BM109
FACS sorted CD (45+/34-/33+/11b-/15+)  from Bone marrow RN20-BM080
FACS sorted CD (45+/34+/33+)  from PBMC RN3-5
FACS sorted CD (45+/34+/33+) from PBMC RN2-13Lb
FACS sorted CD (45+/34+/33+)  from PBMC RN1-13-La
293 PTBP1 and PTBP2 double knockdown with exon-excluded PTBP1 overexpression_rep2
293 PTBP1 and PTBP2 double knockdown with exon-excluded PTBP1 overexpression_rep1
293 PTBP1 and PTBP2 double knockdown with full-length PTBP1 overexpression_rep2
293 PTBP1 and PTBP2 double knockdown with full-length PTBP1 overexpression_rep1
293 PTBP1 and PTBP2 double knockdown_rep2
293 PTBP1 and PTBP2 double knockdown_rep1
mRNA fibroblasts infected with irradiated virus
mRNA uninfected fibroblasts treated with type 1 interferon
footprints fibroblasts infected for 24hr
footprints fibroblasts infected for 12hr
footprints fibroblasts infected with irradiated virus
footprints uninfected fibroblasts treated with type 1 interferon
Healthy Control PMN from Donor 2 isolated by Polymorphprep, TNF-alpha treated
Healthy Control PMN from Donor 2 isolated by Polymorphprep, GM-CSF treated
Healthy Control PMN from Donor 2 isolated by negative selection, TNF-alpha treated
Healthy Control PMN from Donor 2 isolated by negative selection, GM-CSF treated
Healthy Control PMN from Donor 2 isolated by Polymorphprep, untreated
Healthy Control PMN from Donor 2 isolated by negative selection, untreated
Healthy Control PMN from Donor 1 isolated by Polymorphprep, TNF-alpha treated
Healthy Control PMN from Donor 1 isolated by negative selection, TNF-alpha treated
Healthy Control PMN from Donor 1 isolated by Polymorphprep, GM-CSF treated
Healthy Control PMN from Donor 1 isolated by negative selection, untreated
Healthy Control PMN from Donor 1 isolated by negative selection, GM-CSF treated
Healthy Control PMN from Donor 1 isolated by Polymorphprep, untreated
RNA-seq: Gastric Cancer Cell Line 1 - NCC24
RNA-seq: Gastric Cancer Cell Line 1 - YCCEL1
RNA-seq: Gastric Carcinoma Biopsy 2 - Bioserve
RNA-seq: Gastric Carcinoma Biopsy 1 - Bioserve
matched normal lung tissue from a patient
hTert-immortilized dermal fibroblast SW603 , WT, + siPOLA1; poly(dA:dT), 16 h Sample 26
hTert-immortilized dermal fibroblast SW603 , WT, + siPOLA1; non stimulated Sample 25
hTert-immortilized dermal fibroblast SW606 from XLPDR patient, POLA1-deficient, poly(dA:dT), 16 h Sample 24
hTert-immortilized dermal fibroblast SW606 from XLPDR patient, POLA1-deficient, non stimulated Sample 23
hTert-immortilized dermal fibroblast SW603 , WT, + siPOLA1; TNF (1000 U/mL), 12 h Sample 22
hTert-immortilized dermal fibroblast SW603 , WT, + siPOLA1; TNF (1000 U/mL), 2 h Sample 21
hTert-immortilized dermal fibroblast SW603 , WT, + siPOLA1; non stimulated Sample 20
hTert-immortilized dermal fibroblast SW606 from XLPDR patient, POLA1-deficient, TNF (1000 U/mL), 12 h Sample 19
hTert-immortilized dermal fibroblast SW606 from XLPDR patient, POLA1-deficient, TNF (1000 U/mL), 2 h Sample 18
hTert-immortilized dermal fibroblast SW606 from XLPDR patient, POLA1-deficient, non stimulated Sample 17
hTert-immortilized dermal fibroblast SW606 from XLPDR patient, POLA1-deficient, non stimulated Sample 16
Primary dermal fibroblasts SW1756 from XLPDR patient, POLA1-deficient, non stimulated Sample 15
hTert-immortilized dermal fibroblast SW603 , WT, + siControl; poly(dA:dT), 16 h Sample 14
hTert-immortilized dermal fibroblast SW603 , WT, + siControl; non stimulated Sample 13
hTert-immortilized dermal fibroblast SW603 , WT, poly(dA:dT), 16 h Sample 12
hTert-immortilized dermal fibroblast SW603 , WT, non stimulated Sample 11
hTert-immortilized dermal fibroblast SW603 , WT, + siControl; TNF (1000 U/mL), 12 h Sample 10
hTert-immortilized dermal fibroblast SW603 , WT, + siControl; TNF (1000 U/mL), 2 h Sample 9
hTert-immortilized dermal fibroblast SW603 , WT, + siControl; non stimulated Sample 8
hTert-immortilized dermal fibroblast SW603 , WT, TNF (1000 U/mL), 12 h Sample 7
hTert-immortilized dermal fibroblast SW603 , WT, TNF (1000 U/mL), 2 h Sample 6
hTert-immortilized dermal fibroblast SW603 , WT, non stimulated Sample 5
hTert-immortilized dermal fibroblast SW603 , WT, non stimulated Sample 4
Primary dermal fibroblast “C” , WT, non stimulated Sample 3
Primary dermal fibroblast “B” , WT, non stimulated Sample 2
Primary dermal fibroblast “A”, WT, non stimulated Sample 1
RNA-seq in LCL, control shRNA, replicate 1
RNA-seq in LCL, EBNA1 shRNA, replicate 2
RNA-seq in LCL, EBNA1 shRNA, replicate 1
RNA-seq in LCL, control shRNA, replicate 2
BJ RASG12V + CRISPR sgRNA p21enhancer_Tiling_Hit147
BJ RASG12V + CRISPR sgRNA p21enhancer_Tiling_Hit38
BJ RASG12V + CRISPR sgRNA p21enhancer_Tiling_Hit4
BJ RASG12V +  CRISPR sgRNA for Enhancer3507_Hit3
BJ RASG12V +  CRISPR sgRNA for Enhancer3507_Hit2
BJ RASG12V +  CRISPR sgRNA for Enhancer3507_Hit1
subject 17, ADEH-, HSV-1 treatment, rep 2
subject 25, ADEH+, HSV-1 treatment, rep 4
subject 35, ADEH+, HSV-1 treatment, rep 5
subject 152, ADEH+, HSV-1 treatment, rep 2
subject 130, ADEH+, HSV-1 treatment, rep 1
subject 329, ADEH-, HSV-1 treatment, rep 3
subject 88, ADEH-, HSV-1 treatment, rep 6
subject 169, ADEH-, HSV-1 treatment, rep 1
subject 24, ADEH+, HSV-1 treatment, rep 3
subject 152, ADEH+, sham treatment, rep 2
subject 25, ADEH+, sham treatment, rep 4
subject 17, ADEH-, sham treatment, rep 2
subject 373, ADEH-, HSV-1 treatment, rep 4
subject 58, ADEH-, HSV-1 treatment, rep 5
subject 130, ADEH+, sham treatment, rep 1
subject 329, ADEH-, sham treatment, rep 3
subject 24, ADEH+, sham treatment, rep 3
subject 88, ADEH-, sham treatment, rep 6
subject 169, ADEH-, sham treatment, rep 1
subject 35, ADEH+, sham treatment, rep 5
subject 373, ADEH-, sham treatment, rep 4
subject 58, ADEH-, sham treatment, rep 5
strand specific RNA-Seq for MRG replicate 1
strand specific RNA-Seq for MRG replicate 2
strand specific RNA-Seq for NE replicate 1
strand specific RNA-Seq for MRG derived neuronal like populations replicate 1
strand specific RNA-Seq for ERG replicate 1
strand specific RNA-Seq for ERG derived neuronal like populations replicate 2
strand specific RNA-Seq for MRG derived neuronal like populations replicate 2
strand specific RNA-Seq for LRG derived astrocyte like populations replicate 2
strand specific RNA-Seq for ESCs replicate 1
strand specific RNA-Seq for ERG replicate 2
strand specific RNA-Seq for NE derived neuronal like populations replicate 2
strand specific RNA-Seq for NE replicate 2
strand specific RNA-Seq for ESCs replicate 2
strand specific RNA-Seq for LRG replicate 3
strand specific RNA-Seq for LRG replicate 1
strand specific RNA-Seq for ERG derived neuronal like populations replicate 1
strand specific RNA-Seq for LRG derived astrocyte like populations replicate 1
strand specific RNA-Seq for LRG replicate 2
strand specific RNA-Seq for NE derived neuronal like populations replicate 1
Footprint for vehicle treated PC3 cells, replicate #1.
shControl for shAML1-ETO, shE2A, shLYL1, shLDB1 and shLMO2
footprints fibroblasts infected for 72hr